{
    "nctId": "NCT06229392",
    "briefTitle": "A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer",
    "officialTitle": "A Phase I Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Breast Cancer Triple Negative",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 18,
    "primaryOutcomeMeasure": "Dose- limiting toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* ECOG 0-2\n* Patients must be planning to receive standard of car e neoadjuvant chemotherapy as defined by the most recent version of NCCN guidelines (www.nccn.org)\n* Patients must have histologically or cytologically confirmed invasive breast cancer that is either triple-negative or HER2+ (regardless of hormone receptor status)\n\nExclusion Criteria:\n\n* Patients with any uncontrolled intercurrent illness.\n* Patients who have any underlying medical condition for which, in the investigator's opinion, participation would not be in the best interest of the participant\n* History of egg allergy\n* Patients currently on anticoagulant therapy, corticosteroids, or immunosuppressive agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the seasonal flu vaccine.\n* History of Guillain-Barr\u00e9 syndrome",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}